NEW YORK (GenomeWeb) – Australian molecular diagnostics firm Genetic Technologies announced today that it has partnered with the University of Melbourne to broaden the applicability of its BrevaGenplus breast cancer risk assessment test.
Genetic Technologies' BrevaGenplus is currently designed for women aged 35 years or older who have not had breast cancer but who have one or more risk factors. In collaboration with the University of Melbourne, the company is aiming to expand the test's use to women with an extended family history of the disease, and increase the range of risk factors analyzed by the test.
Additional terms of the deal were not disclosed.
In addition to BrevaGenplus, Genetic Technologies is developing a colorectal cancer risk assessment test. The company also recently partnered with Omix Ventures to develop and access a blockchain-based global genomic data management platform for cancer diagnostic development.